低剂量卡培他滨治疗晚期乳腺癌患者的 II 期单臂试验
This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.
研究概览
详细说明
The study is a phase II, single arm study in which all patients will receive the study drug. Participants will include older/frail patients with metastatic breast cancer.
All patients will be treated with capecitabine 1000 mg daily. There will be a total of 40 participants with measurable disease on this trial.
The study will encompass participants with locally advanced unresectable/metastatic breast cancer with measurable disease, who progressed on at least 1 prior therapy in the metastatic setting. Breast cancer subtypes include HR+ HER2 negative, or TNBC, age ≥ 60 years old, or frail patients at a younger age. ECOG PS 0- 2.
The study will discontinue if progressive disease or unacceptable toxicity is noted.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Margaret Thomas, MPH
- 电话号码:205-895-1802
- 邮箱:margaretathomas@uabmc.edu
研究联系人备份
- 姓名:Katia Khouri, MD
- 电话号码:216-556-3035
- 邮箱:katia.khoury@gunet.georgetown.edu
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- University of Alabama at Birmingham
-
副研究员:
- Katia Khoury, MD
-
副研究员:
- Gabrielle Rocque, MD
-
接触:
- Humaria Sarfraz, MD
- 电话号码:205-975-2891
- 邮箱:humairasarfraz@uabmc.edu
-
首席研究员:
- Humaria Sarfraz, MD
-
副研究员:
- Mauricio Escobar, MD
-
副研究员:
- Nustrat Jahan, MD
-
副研究员:
- Erica Stringer-Reasor, MD
-
副研究员:
- Allison Richard, MD
-
副研究员:
- Lisle Nabell, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Histologically or cytologically confirmed breast cancer with HER2 negative status. A copy of the pathology report is required at the time of enrollment.
- HER2 negativity will be determined by in situ hybridization (ISH) non- amplified and IHC 0 or 1+ or 2+.
- Patients with HR (hormone receptor) positive and triple negative breast cancer (TNBC) will be eligible for enrollment.
-
Metastatic or locally advanced breast cancer, with at least one measurable lesion according to RECIST (v1.1).
-
ECOG performance status of 0-2.
-
Patients must have progressed on at least 1 prior line of therapy in the metastatic setting (hormonal therapy or chemotherapy)
-
Adequate organ function as evidenced by:
-
ANC >1.5 x 10⁹/L (1500/µL) or > 1.3 x 10⁹/L (1300/µL) for patients with history of benign ethnic neutropenia.
-
Platelet count ≥100,000/µL (without transfusion within 2 weeks prior to initiation of study treatment (Cycle 1, day 1)).
-
Hemoglobin ≥9.0 g/dl. Patients may be transfused or receive erythropoietic treatment to meet this criterion.
-
AST, ALT, and alkaline phosphatase ≤2.5 x upper limit of normal (ULN) with following exceptions: I. Patients with documented liver metastasis: AST and ALT ≤5 x ULN II. Patients with documented liver or bone metastasis: alkaline phosphatase ≤5 x ULN
-
Serum bilirubin ≤1.5 x ULN
• Patients with known Gilbert disease who have serum bilirubin level ≤3 x ULN may be enrolled.
-
INR and aPTT ≤1.5 x ULN
• This applies only to the patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
-
Creatinine clearance > 30 mL/min (measured using Cockcroft-Gault equation or estimated glomerular filtration rate from the Modification of Diet in Renal Disease Study)
-
-
Patients must be able to provide signed informed consent.
-
Female patients of any ethnic group. Female patients must be surgically sterile, postmenopausal (no menses for at least one year), or using medically approved method of contraception (excluding rhythm, withdraw or abstinence). Men must agree to use a medically approved method of contraception (excluding rhythm, withdraw or abstinence).
-
Patients ≥60 years old and/or frail patients at any age, defined by the investigator as an individual at greater risk of complications and poorer outcomes with systemic therapy, secondary to a lower physiologic reserve and higher comorbidities and functional deficits.
-
Complete initial work-up within 2 weeks prior to start of treatment (Cycle 1 Day 1).
-
Patients known to be HIV positive are eligible if they meet the inclusion criteria.
Exclusion Criteria:
- Any history of treatment with Capecitabine in metastatic setting.
- Patients who only have non-measurable disease.
- Patients with severe hepatic (bilirubin > 3 times upper limit of normal) or renal failure (CrCl < 30 calculated using Cockcroft-Gault formula).
- Patients who are unable to swallow pills
- Patients with HER2 positive breast cancer
- Major surgical procedure within 3 weeks prior to study entry.
- Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >2 weeks prior to initiation of study treatment (Cycle 1, Day 1)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Low dose capecitabine (Xeloda)
1000 mg capecitabine daily by mouth. |
Will be given once per day by mouth
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response rate (RR) evaluation
大体时间:Baseline up to 12 weeks
|
Evaluate response rate (RR) as defined per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (v 1.1). Response and progression of disease will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee; version 1.1. Patients will be evaluated for response every 12 weeks per RECIST Criteria. |
Baseline up to 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS)
大体时间:Up to 36 months
|
Initiation of treatment to the occurrence of disease progression or death. The RECIST v. 1.1 criteria will be used to evaluate progression-free survival as well as CT and PET scans. Baseline to the date of first documented progression to date of death from any cause, whichever comes first, assessed up to 36 months. |
Up to 36 months
|
|
Overall survival (OS)
大体时间:Baseline up to 36 months
|
The time which begins at diagnosis (or at the start of treatment) and up to the time of death. |
Baseline up to 36 months
|
|
Number of adverse events
大体时间:Baseline up to 36 months
|
Incidence of Treatment-Emergent Adverse Events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. Safety, tolerability, satisfaction, and quality of life assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) questionnaire, as well as the PRO-CTCAE (Patient reported outcomes - Common Terminology Criteria for Adverse Events) questionnaire. |
Baseline up to 36 months
|
合作者和调查者
调查人员
- 首席研究员:Humaria Sarfraz, MD、The University of Alabama at Birmingham
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRB-300012026 (UAB23115)
- Breast Cancer Foundation (其他标识符:Breast Cancer Foundation)
- Robert Award (其他标识符:UAB Cancer Center)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.